Experiment A. You replace spiperone with a radiolabelled drug that has a higher affinity for the D₂ receptor. Experiment B. You replace spiperone with a radiolabelled drug that has a lower affinity for the D₂ receptor. Experiment C. The drug used in the experiment was spiperone, but the cells used to make the protein preparation expressed higher levels of the D₂ receptor. Experiment D. The drug used in the experiment had the same affinity for the D₂ receptor as spiperone, but had a higher efficacy.

Experiment A. You replace spiperone with a radiolabelled drug that has a higher affinity for the D₂ receptor. Experiment B. You replace spiperone with a radiolabelled drug that has a lower affinity for the D₂ receptor. Experiment C. The drug used in the experiment was spiperone, but the cells used to make the protein preparation expressed higher levels of the D₂ receptor. Experiment D. The drug used in the experiment had the same affinity for the D₂ receptor as spiperone, but had a higher efficacy.

Biochemistry

9th Edition

ISBN:9781319114671

Author:Lubert Stryer, Jeremy M. Berg, John L. Tymoczko, Gregory J. Gatto Jr.

Publisher:Lubert Stryer, Jeremy M. Berg, John L. Tymoczko, Gregory J. Gatto Jr.

Chapter1: Biochemistry: An Evolving Science

Section: Chapter Questions

Problem 1P

See similar textbooks

Similar questions

You are a technician in a biochemistry lab running receptor binding experiments. The target membrane-bound receptor has been partially purified from mouse, rat, and human cell lines. Using the same radioactive ligand in a saturation binding assay for each species' receptor, you generate the binding data in the table. The dependent variable, Y, is the fraction of binding sites occupied by the ligand. Ligand Y for mouse Y for rat Y for human concentration receptor receptor receptor (nM) 0.20 0.048 0.29 0.17 0.50 0.11 0.50 0.33 1.0 0.20 0.67 0.50 4.0 0.50 0.89 0.80 10 0.71 0.95 0.91 20 0.83 0.97 0.95 50 0.93 0.99 0.98 Determine the Ka for the human receptor in this binding experiment. human receptor Kd nM
Pathway analysis: Link the protein names to the correct statements by interrogating the depicted pathway. Options: A. RTK Receptor Threonine Kinase B. GEF Guanidine Exchange Factor C. PLC Phospholipase C D. GAP GTPase Activating Protein E. Gαi F. Raf Rapidly Accelerated Fibrosarcoma G. PAK1 p21 Activated Kinase H. WASP Wiscott Aldrich syndrome protein I. RTK Receptor Tyrosine Kinase J. GPCR G-protein Coupled Receptor K. Steroid Receptor L. Phosphatase M. MEK1 (Mitogen-Activated Protein) Kinase/ERK (Extracellular Signal-Regulated Kinase) Kinase 1 N. AC Adenylyl cyclase O. IP3R IP3 Receptor P. ERK1/2 Extracellular Signal-Regulated Kinase
My boss has given me the purified extracellular portion of the Notch receptor. As Delta/Notch signaling occurs between cells, I know that both the Notch receptor and and Delta are most likely "comfortable" in the environment of the blood, not the cytosol, nucleus, mitochondria, etc... I want to purify Delta, the signal. What would be true of the most specific purification technique I could choose, i.e. the technique that will result in the fewest proteins in the fraction containing Delta? Do not worry about whether the protein works after fractionation yet. Pick ALL that apply. I would use ion exchange chromatography. I would use size exclusion chromatography I would use affinity chromatography I would use a water based mobile phase of 7.4 I would use an acetonitrile mobile phase with a pH of 7.4 I would use a water based mobile phase of pH 7.2 I would use an acetonitrile phase of 7.2 I…
Place the steps below in the correct order as they would occur within a signal transduction pathway. Drag and drop options into correct order and submit. For keyboard navigation... SHOW MORE ♥ An inactive signal transduction molecule is activated. A transcription factor enters the nucleus. An active signal transduction molecule binds a transcription factor. A gene is expressed. A receptor undergoes a conformational change. A ligand binds to a receptor. [3 Fuls Your answer II II II II II
The above answer did not address the question in the sense that the answer did not indicate which protein involved in the pathways could be measured in the nucleus of cells and be confident in the results? I reiterate the question as follows: You want to do a single Western blot to measure changes in signaling activity, regardless of which pathway is being activated. For which protein involved in these pathways could you measure the levels in the nucleus of cells and be confident in your results? Why?
Two GPCR mutations (Mutant A and Mutant B) were tested for activity. One was confirmed as being a constitutively activating, gain of function GPCR mutation and one was confirmed as being a loss of function GPCR mutation. Which is which? Explain your answer.
Concider the scenario and answer the questions: You are trying to build a new drug to stop cancer cells from proliferating and you are focusing onone receptor in the cell membrane. Your drug seems to not allow component A to bind to thereceptor and it causes no proliferation. When you study more in detail the cancer cells, you realizethat ATP is not binding to the receptor when you add the drug to your cell sample. Based on theinformation provided. What type of receptor does component A bind to?. What type of molecule is the drug?
Cancer stem cells (CSCs) are cancer cells (found within tumors or hematological cancers) that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. There are many biomedical engineering based approaches to detect CSCs. Question: What kind of systems have been developed to detect CSCs? Describe by giving examples. Please explain with a few examples.
Which ONE of these statements is the most accurate definition of the mode of action of imatinib? Select one: A.It is a specific inhibitor of the BCR‐ABL1 fusion protein and blocks phosphatase activity by competing with adenosine triphosphate (ATP) binding B.It is a specific inhibitor of the BCR‐ABL1 fusion protein and blocks tyrosine kinase activity by competing with adenosine triphosphate (ATP) binding C.It is a specific inhibitor of the BCR‐ABL1 fusion protein and blocks tyrosine kinase activity by interaction with the enzyme site D.It is a specific inhibitor of the BCR‐ABL1 fusion protein and blocks phosphatase activity by interaction with the enzyme site
You perform a competition study on a GPCR. You have isolated the plasma membrane from cells which contains the GPCR of interest. If an agonist and an inverse agonist are at equal concentrations in your study but the inverse agonist has a 10 x higher affinity for the receptor than the agonist, what would you expect to be the overall outcome to be? More of the agonist is bound and so most of the receptor is in its active conformation and is stimulated More of the inverse agonist is bound and so most of the receptor is in its inactive conformation and is unstimulated.
What would be the effect of inhibiting the kinase?
Describe how the GPCR and MAPK pathways 'cross-talk' or interact with each other. Give support for your statements. Is cross-talk relevant for drug design? Why or why not?